Technology ID
TAB-3226

Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development

E-Numbers
E-178-2016-0
Lead Inventor
Kinney, Claire (CDC)
Applications
Vaccines­­­
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Lead IC
CDC
ICs
CDC
Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections.

CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53) for potential development of a live-attenuated Zika vaccine. These chimeric viruses could also be used for other research purposes such as development of diagnostic tests. The cDNA genetic clones for the chimeric constructs have been successfully engineered, and scientists in the laboratory are in the process of deriving infectious chimeric D2 PDK-53/Zika viruses.
Commercial Applications
  • Zika vaccine development or combined vaccination strategies using both live-attenuated and inactivated ZIKV vaccine (West Nile/ZKV) candidates
  • Combination vaccine with other flaviviruses such as dengue or chikungunya
  • Zika virus diagnostics
  • Zika virus-related biomedical research
Competitive Advantages
  • Potential inclusion in combination flavivirus vaccines
  • Faster production of Zika-like viruses for more efficient use in different applications such as vaccine candidate and diagnostic development

Request More Info

Licensing Contact:
Mitzelfelt, Jeremiah
jeremiah.mitzelfelt@nih.gov

Related Inventions

Patents

  • US
    Provisional (PRV) 62/359,812
    Filed on 2016-07-08
  • Patent Cooperation Treaty
    (PCT) PCT/US2017/040820
    Filed on 2017-07-06
  • US Patent 11,344,615
    Filed on 2019-01-07

Publications

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Chimeric Dengue/Zika Viruses for Zika Vaccine Development. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.
Date Published